The Current Strategy for Managing Pancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Multiple endocrine neoplasia type 1 (MEN1) is an inherited autosomal dominant disease presenting with pancreatic neuroendocrine tumors (pNETs), parathyroid tumors, or pituitary tumors. Using the PubMed database, we reviewed the literature on information regarding the proper diagnosis and treatment of MEN1-associated pNET. Many cases of MEN1-associated pNET are functioning pNETs. Gastrinomas and insulinomas tend to occur frequently in the duodenum and pancreas, respectively. In addition to diagnostic imaging, the selective arterial secretagogue injection test (SASI test) is useful for localizing functioning pNET. The standard treatment is surgical resection. However, in the case of a functioning pNET, the tumor should first be accurately located using the SASI test before an appropriate surgical method is selected. In cases of a MEN1-associated non-functioning pNET that exceeds 2 cm in diameter, the incidence of distant metastasis is significantly increased, and surgery is recommended. In cases of unresectable pNET, a somatostatin analog has been shown to demonstrate antitumor effects and is considered to be a promising treatment. In addition, molecular-targeted drugs have recently been found to be effective in phase III clinical trials.
Abstract
Multiple endocrine neoplasia type 1 (MEN1) is an inherited autosomal dominant disease presenting with pancreatic neuroendocrine tumors (pNETs), parathyroid tumors, or pituitary tumors. Using the PubMed database, we reviewed the literature on information regarding the proper diagnosis and treatment of MEN1-associated pNET. Many cases of MEN1-associated pNET are functioning pNETs. Gastrinomas and insulinomas tend to occur frequently in the duodenum and pancreas, respectively. In addition to diagnostic imaging, the selective arterial secretagogue injection test (SASI test) is useful for localizing functioning pNET. The standard treatment is surgical resection. However, in the case of a functioning pNET, the tumor should first be accurately located using the SASI test before an appropriate surgical method is selected. In cases of a MEN1-associated non-functioning pNET that exceeds 2 cm in diameter, the incidence of distant metastasis is significantly increased, and surgery is recommended. In cases of unresectable pNET, a somatostatin analog has been shown to demonstrate antitumor effects and is considered to be a promising treatment. In addition, molecular-targeted drugs have recently been found to be effective in phase III clinical trials.
참고문헌 (44)
- Wermer P, "Genetic aspects of adenomatosis of endocrine glands", Am J Med, 16, pp.363~371 (1954)
- Sipple JH, "The association of pheochromocytoma with carcinoma of the thyroid gland", Am J Med, 31, pp.163~166 (1961)
- Chandrasekharappa SC, "Positional cloning of the gene for multiple endocrine neoplasia-type 1", Science, 276, pp.404~407 (1997)
- Cavallari I, "In situ analysis of human menin in normal and neoplastic pancreatic tissues: evidence for differential expression in exocrine and endocrine cells", J Clin Endocrinol Metab, 88, pp.3893~3901 (2003)
- Marx SJ, "Molecular genetics of multiple endocrine neoplasia types 1 and 2", Nat Rev Cancer, 5, pp.367~375 (2005)
- Poisson A, "Menin interacting proteins as clues toward the understanding of multiple endocrine neoplasia type 1", Cancer Lett, 189, pp.1~10 (2003)
- Tsukada T, "The MEN1 gene and associated diseases: an update", Endocr Pathol, 12, pp.259~273 (2001)
- Trump D, "Clinical studies of multiple endocrine neoplasia type 1 (MEN1)", QJM, 89, pp.653~669 (1996)
- Bassett JH, "Characterization of mutations in patients with multiple endocrine neoplasia type 1", Am J Hum Genet, 62, pp.232~244 (1998)
- Brandi ML, "Guidelines for diagnosis and therapy of MEN type 1 and type 2", J Clin Endocrinol Metab, 86, pp.5658~5671 (2001)
- Ito T, "Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan", J Gastroenterol, 45, pp.234~243 (2010)
- Marx S, "Multiple endocrine neoplasia type 1: clinical and genetic topics", Ann Intern Med, 129, pp.484~494 (1998)
- Marini F, "Multiple endocrine neoplasia type 1", Orphanet J Rare Dis, 1, pp.38~ (2006)
- Doherty GM, "Rare endocrine tumours of the GI tract", Best Pract Res Clin Gastroenterol, 19, pp.807~817 (2005)
- Tonelli F, "Pancreatic endocrine tumors in multiple endocrine neoplasia type 1 syndrome: review of literature", Endocr Pract, 17(Suppl 3), pp.33~40 (2011)
- Jensen RT, "Management of the Zollinger-Ellison syndrome in patients with multiple endocrine neoplasia type 1", J Intern Med, 243, pp.477~488 (1998)
- Metz DC, "Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors", Gastroenterology, 135, pp.1469~1492 (2008)
- Pieterman CR, "Care for patients with multiple endocrine neoplasia type 1: the current evidence base", Fam Cancer, 10, pp.157~171 (2011)
- Akerström G, "Timing and extent of surgery in symptomatic and asymptomatic neuroendocrine tumors of the pancreas in MEN 1", Langenbecks Arch Surg, 386, pp.558~569 (2002)
- Frankton S, "Gastrointestinal endocrine tumours. Glucagonomas", Baillieres Clin Gastroenterol, 10, pp.697~705 (1996)
- Dean PG, "Are patients with multiple endocrine neoplasia type I prone to premature death?", World J Surg, 24, pp.1437~1441 (2000)
- Doherty GM, "Lethality of multiple endocrine neoplasia type I", World J Surg, 22, pp.581~586 (1998)
- Grant CS, "Insulinoma. The value of intraoperative ultrasonography", Arch Surg, 123, pp.843~848 (1988)
- Kuzin NM, "Preoperative and intraoperative topographic diagnosis of insulinomas", World J Surg, 22, pp.593~597 (1998)
- Khashab MA, "EUS is still superior to multidetector computerized tomography for detection of pancreatic neuroendocrine tumors", Gastrointest Endosc, 73, pp.691~696 (2011)
- Wiesli P, "Selective arterial calcium stimulation and hepatic venous sampling in the evaluation of hyperinsulinemic hypoglycemia: potential and limitations", J Vasc Interv Radiol, 15, pp.1251~1256 (2004)
- Imamura M, "Usefulness of selective arterial secretin injection test for localization of gastrinoma in the Zollinger-Ellison syndrome", Ann Surg, 205, pp.230~239 (1987)
- Doppman JL, "Insulinomas: localization with selective intraarterial injection of calcium", Radiology, 178, pp.237~241 (1991)
- Imamura M, "Recent standardization of treatment strategy for pancreatic neuroendocrine tumors", World J Gastroenterol, 16, pp.4519~4525 (2010)
- Baba Y, "Localization of insulinomas. Comparison of conventional arterial stimulation with venous sampling (ASVS) and superselective ASVS", Acta Radiol, 41, pp.172~177 (2000)
- Norton JA, "Surgery to cure the Zollinger-Ellison syndrome", N Engl J Med, 341, pp.635~644 (1999)
- Norton JA, "Comparison of surgical results in patients with advanced and limited disease with multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome", Ann Surg, 234, pp.495~505 (2001)
- Durante C, "Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma", Endocr Relat Cancer, 16, pp.585~597 (2009)
- Akerström G, "Pancreatic tumours as part of the MEN-1 syndrome", Best Pract Res Clin Gastroenterol, 19, pp.819~830 (2005)
- Thompson NW, "Surgical treatment of the endocrine pancreas and Zollinger-Ellison syndrome in the MEN 1 syndrome", Henry Ford Hosp Med J, 40, pp.195~198 (1992)
- Bartsch DK, "Pancreaticoduodenal endocrine tumors in multiple endocrine neoplasia type 1: surgery or surveillance?", Surgery, 128, pp.958~966 (2000)
- Imamura M, "Biochemically curative surgery for gastrinoma in multiple endocrine neoplasia type 1 patients", World J Gastroenterol, 17, pp.1343~1353 (2011)
- Plöckinger U, "Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS)", Neuroendocrinology, 80, pp.394~424 (2004)
- Rinke A, "Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group", J Clin Oncol, 27, pp.4656~4663 (2009)
- Moertel CG, "Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma", N Engl J Med, 326, pp.519~523 (1992)
- Arnold R, "Endocrine tumours of the gastrointestinal tract: chemotherapy", Best Pract Res Clin Gastroenterol, 19, pp.649~656 (2005)
- Yalcin S, "Advances in the systemic treatment of pancreatic neuroendocrine tumors", Cancer Treat Rev, 37, pp.127~132 (2011)
- Yao JC, "Everolimus for advanced pancreatic neuroendocrine tumors", N Engl J Med, 364, pp.514~523 (2011)
- Raymond E, "Sunitinib malate for the treatment of pancreatic neuroendocrine tumors", N Engl J Med, 364, pp.501~513 (2011)